title: Possible interventional therapies in severe sepsis or septic shock.
abstract: For many years, basic research with relatively straightforward pathophysiologic approaches has driven clinical trials using molecules that supposedly interfere positively with inflammatory processes. However, most of these trials have failed to demonstrate any outcome benefit. Indeed, we need to revisit current paradigms and to think about the possibility that outcome may be predetermined in severe sepsis or septic shock. In addition, an early diagnosis of sepsis prior to the onset of clinical decline is also of particular interest to health practitioners because this information increases the possibilities for early and specific treatment of this life threatening condition. Indeed, the time to initiate therapy is thought to be crucial and the major determent factor in surviving sepsis. Despite substantial progress in sepsis therapy, the gap between the discovery of new effective medical molecules and their implementation in the daily clinical practice of the intensive care unit remains a major hurdle. Fortunately, ongoing research continues to provide new information on the management of sepsis, in particular, severe sepsis or septic shock. High quality and effective management tools are necessary to bring evidence-based therapy to the bedside. On this basis, new therapies could be tested to reduce mortality rates with respect to recently published studies.
authors: Department of Pharmacology, National Defense Medical Center, Neihu, Taipei, Taiwan, ROC. ccwu@mail.ndmctsgh.edu.tw
authors: Chin-Chen
authors: CC
authors: Wu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use; D016328:NF-kappa B / Q000502:physiology; D018805:Sepsis / Q000628:therapy*; D012772:Shock, Septic / Q000628:therapy*; D014667:Vasopressins / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D006895:Hydroxyethyl Starch Derivatives; D016328:NF-kappa B; D014667:Vasopressins